Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)
Sponsor: Diwakar Davar
A PHASE2 clinical study on Uveal Melanoma, this trial is actively recruiting participants. The trial is conducted by Diwakar Davar and has accumulated 11 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Apr 2025 — Jan 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2025 — Apr 2025 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Not Yet Recruiting PHASE2
▶ Show 6 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — Apr 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Diwakar Davar
- Immunocore Ltd
For direct contact, visit the study record on ClinicalTrials.gov .